OTCPK:NEPTF - Post by User
Post by
Francine01on Nov 17, 2017 11:48am
![](https://assets.stockhouse.com/kentico-cms/0338-00/images/Sprite.svg#id_Post_Views_Icon)
105 Views
Post# 26984385
Acasti amended prospectus for 11,700,000 shares
Acasti amended prospectus for 11,700,000 sharesAcasti amended is prospectus and specified 11,700,000 share.
Doing the math with 25,000,000 shares, Neptune would fall under the 20% ownership and avoid consolidation of R&D losses.
Since all the potential of Acasti and proably get some phase 3 results in 2018, I am not sure if a dillution for Neptune is a good news with all the cash that Neptune have.
Best option for Acasti, would be to be purchase by a major pharma just before end of phase 3, so Neptune shareholders will cash.
Any thoughts on this ?